What did @drmaryclaire actually say?
In a short follow-up clip, Dr. Mary Claire explains that she monitors estradiol levels in patients after starting hormone therapy, and she frames her reasoning around two things: "prevention and science." She references a previous video that apparently gained significant traction, and she directed viewers to a Substack post where she laid out the studies behind her approach and offered guidance on how patients can talk to their own doctors.
To be clear about what she did not say in this clip: she did not name a specific hormone, a dose, a condition, or a study. This is essentially a teaser and a redirect. So any fact-check of this clip is necessarily limited. We are evaluating the framing and the implied claim, not a detailed clinical argument she has not yet made on camera here.
Still, the core implied claim is worth examining: that monitoring estradiol after initiating hormone therapy is scientifically justified and clinically important. That is a reasonable and defensible position. It is also one that is genuinely contested in terms of how and when to test, and what to do with the results.
Does the science back this up?
Yes, with some important caveats about what "monitoring estradiol" actually tells you and when it matters. Estradiol is the primary biologically active estrogen, and its levels shift significantly depending on the route and type of hormone therapy used. For women on oral estrogen, serum estradiol levels are notoriously unreliable as a clinical guide because of first-pass liver metabolism. For transdermal preparations, levels are more stable and more reflective of systemic exposure.
A 2019 paper by Stuenkel et al. in the Journal of Clinical Endocrinology and Metabolism noted that while symptom relief remains the primary endpoint for menopausal hormone therapy, serum estradiol can be a useful adjunct when patients are not responding as expected or when safety concerns arise. The Menopause Society (formerly NAMS) has similarly noted that routine monitoring is not universally required but may be appropriate in specific clinical scenarios, such as unexpectedly high levels that could indicate over-absorption with transdermal gels or patches.
Where this gets complicated is in testosterone therapy for women. When women receive testosterone, a portion converts to estradiol via aromatization. Monitoring estradiol in that context is not just reasonable, it is arguably necessary if you want to understand the patient's full hormonal picture.
What did they get wrong (or right)?
Given that this clip is essentially a teaser for a longer written piece, it is hard to find something specifically wrong here. What she said, that she monitors estradiol for reasons of "prevention and science," is not inaccurate. It is also not especially informative in isolation.
The credit she deserves: she is directing viewers to primary sources rather than asking them to just take her word for it. That matters. Too many hormone-focused social media accounts operate entirely on authority and anecdote. Pointing people toward studies is the right instinct, even if the clip itself does not make a falsifiable claim.
The mild concern: the framing of an "emergency sub-stack" in response to a viral video is a pattern worth watching. When clinical content goes viral and a creator rushes to publish follow-up material, accuracy can sometimes take a back seat to momentum. We have not reviewed that Substack post, so we cannot evaluate it here. But the pace and framing are worth noting as a prompt for reader caution, not as evidence of wrongdoing.
What should you actually know?
If your provider is monitoring your estradiol during hormone therapy, that is not unusual or alarmist. It can be a reasonable clinical tool, particularly if you are on testosterone therapy, which aromatizes to estradiol, or if you are using transdermal estrogen and your symptoms are not resolving as expected.
What it is not: a universally required test, or one that should be interpreted without clinical context. A single number on a lab report is not a treatment plan. Estradiol levels fluctuate based on timing of the test relative to application of a patch or gel, the assay used by the lab, and your individual metabolism. Some labs use immunoassay methods that are less precise at lower concentrations. For more accurate results, particularly in women using low-dose therapy, the Endocrine Society has recommended mass spectrometry-based assays, as noted by Santen et al. in a 2012 Journal of Clinical Endocrinology and Metabolism review.
The bottom line is that monitoring estradiol is a tool, not a treatment. Whether it is appropriate for you depends on your specific therapy, your symptoms, and your provider's clinical judgment.